| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell and Tumor Biology |
1 Genitourinary Oncology Service; Departments of 2 Pathology and 3 Molecular Biology, Memorial Sloan-Kettering Cancer Center; and 4 Arthritis and Tissue Degeneration Program and Departments of Medicine and Physiology & Biophysics, Hospital for Special Surgery at Weill Medical College of Cornell University, New York, New York
Requests for reprints: Carl P. Blobel, Arthritis and Tissue Degeneration Program and Departments of Medicine and Physiology & Biophysics, Hospital for Special Surgery, Weill Medical College of Cornell University, Room 426, Caspary Research Building, 535 East 70th Street, New York, NY 10021. Phone: 212-606-1429; Fax: 212-774-2560; E-mail: blobelc{at}hss.edu.
ADAM9 is a membrane-anchored metalloprotease that is markedly up-regulated in several human carcinomas. Here, we show that ADAM9 is similarly up-regulated in mouse models for prostate, breast, and intestinal carcinoma. To assess whether ADAM9 is critical for the pathogenesis of prostate carcinoma, one of the most common cancers in men, we evaluated how loss of ADAM9 affects tumorigenesis in W10 mice, a mouse model for this disease. In the absence of ADAM9, most tumors in 50-week-old W10 mice were well differentiated, whereas littermate controls expressing wild-type ADAM9 had predominantly poorly differentiated, and in some cases significantly larger, tumors. Moreover, gain-of-function experiments in which ADAM9 was overexpressed in mouse prostate epithelium resulted in significant abnormalities, including epithelial hyperplasia at 4 to 6 months of age, and prostatic intraepithelial neoplasia after 1 year. A potential underlying mechanism for the role of ADAM9 in prostate cancer emerged from cell-based assays: ADAM9 can cleave and release epidermal growth factor and FGFR2iiib from cells, both of which have pivotal functions in the pathogenesis of this disease. Taken together, these results suggest that ADAM9 contributes to the pathogenesis of prostate cancer and potentially also other carcinomas, raising the possibility that ADAM9 might be a good target for antitumor drugs.
This article has been cited by other articles:
|
|
 |
|
  T. Maretzky, S. M. Le Gall, S. Worpenberg-Pietruk, J. Eder, C. M. Overall, X.-Y. Huang, Z. Poghosyan, D. R. Edwards, and C. P. Blobel Src Stimulates Fibroblast Growth Factor Receptor-2 Shedding by an ADAM15 Splice Variant Linked to Breast Cancer Cancer Res., June 1, 2009; 69(11): 4573 - 4576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Guaiquil, S. Swendeman, T. Yoshida, S. Chavala, P. A. Campochiaro, and C. P. Blobel ADAM9 Is Involved in Pathological Retinal Neovascularization Mol. Cell. Biol., May 15, 2009; 29(10): 2694 - 2703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Duffy, E. McKiernan, N. O'Donovan, and P. M. McGowan Role of ADAMs in Cancer Formation and Progression Clin. Cancer Res., February 15, 2009; 15(4): 1140 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Najy, K. C. Day, and M. L. Day ADAM15 Supports Prostate Cancer Metastasis by Modulating Tumor Cell-Endothelial Cell Interaction Cancer Res., February 15, 2008; 68(4): 1092 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ali and V. Knauper Phorbol Ester-induced Shedding of the Prostate Cancer Marker Transmembrane Protein with Epidermal Growth Factor and Two Follistatin Motifs 2 Is Mediated by the Disintegrin and Metalloproteinase-17 J. Biol. Chem., December 28, 2007; 282(52): 37378 - 37388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Moss, M. Bomar, Q. Liu, H. Sage, P. Dempsey, P. M. Lenhart, P. A. Gillispie, A. Stoeck, D. Wildeboer, J. W. Bartsch, et al. The ADAM10 Prodomain Is a Specific Inhibitor of ADAM10 Proteolytic Activity and Inhibits Cellular Shedding Events J. Biol. Chem., December 7, 2007; 282(49): 35712 - 35721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. McGowan, B. M. Ryan, A. D.K. Hill, E. McDermott, N. O'Higgins, and M. J. Duffy ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression Clin. Cancer Res., April 15, 2007; 13(8): 2335 - 2343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kawaguchi, K. Horiuchi, J. D. Becherer, Y. Toyama, P. Besmer, and C. P. Blobel Different ADAMs have distinct influences on Kit ligand processing: phorbol-ester-stimulated ectodomain shedding of Kitl1 by ADAM17 is reduced by ADAM19 J. Cell Sci., March 15, 2007; 120(6): 943 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Horiuchi, S. Le Gall, M. Schulte, T. Yamaguchi, K. Reiss, G. Murphy, Y. Toyama, D. Hartmann, P. Saftig, and C. P. Blobel Substrate Selectivity of Epidermal Growth Factor-Receptor Ligand Sheddases and their Regulation by Phorbol Esters and Calcium Influx Mol. Biol. Cell, January 1, 2007; 18(1): 176 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Frohlich, R. Albrechtsen, L. Dyrskjot, L. Rudkjaer, T. F. Orntoft, and U. M. Wewer Molecular Profiling of ADAM12 in Human Bladder Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7359 - 7368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-Y. Sung, H. Kubo, K. Shigemura, R. S. Arnold, S. Logani, R. Wang, H. Konaka, M. Nakagawa, S. Mousses, M. Amin, et al. Oxidative Stress Induces ADAM9 Protein Expression in Human Prostate Cancer Cells Cancer Res., October 1, 2006; 66(19): 9519 - 9526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ohtsu, P. J. Dempsey, and S. Eguchi ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors Am J Physiol Cell Physiol, July 1, 2006; 291(1): C1 - C10. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
